Deals this week: EpimAb Biotherapeutics, Biohaven Pharmaceutical, Zai Lab (Shanghai)

27th April 2017 (Last Updated April 27th, 2017 18:30)

Chinese-based biopharmaceutical company EpimAb Biotherapeutics has completed a series A venture financing round to raise funds required to advance its proprietary bispecific platform technology and develop a pipeline of candidates in immuno-oncology and other therapeutic areas.

Chinese-based biopharmaceutical company EpimAb Biotherapeutics has completed a series A venture financing round to raise funds required to advance its proprietary bispecific platform technology and develop a pipeline of candidates in immuno-oncology and other therapeutic areas.

The company has raised $25m from the round, which was led by Oriza Seed Venture Capital.

US-based biotechnology firm Biohaven Pharmaceutical Holding Company intends to raise between $116.67m and $133.33m through an initial public offering of shares of its common stock.

The company will offer approximately 8.33 million shares priced between $14 and $16 a share in the IPO.

Underwriters have a 30-day option to purchase up to an additional 1.25 million shares in case of any over-allotments.

"US-based biotechnology firm Biohaven Pharmaceutical Holding Company intends to raise between $116.67m and $133.33m through an initial public offering of shares of its common stock."

Chinese-based biopharmaceutical company Zai Lab (Shanghai) has signed a licensing agreement with US-based pharmaceutical company Paratek Pharmaceuticals for the development and commercialisation of the latter’s antibiotic, omadacycline, for Chinese patients.

The company will pay $7.5m upfront to Paratek, in addition to milestone-based payments based on the development and royalty payments based on sales.

US-based clinical-stage pharmaceutical company Karyopharm Therapeutics intends to raise $40m through an underwritten public offering of shares of its common stock in order to fund its clinical development, working capital and general corporate purposes.

Underwriters to the offering have a 30-day option to purchase additional shares worth up to $6m.

US-based clinical-stage medical dermatology and aesthetics company Sienna Biopharmaceuticals has completed a series B venture financing round led by ARCH Venture Partners and VenVest Capital to raise funds to advance its topical biotech pipeline.

The company has raised $40m from the financing round.